CAR T-Cell Therapy in China - Comprehensive Guide

info@cancerfax.com

+1-213-789-56-55

WhatsApp Available

CAR T-Cell Therapy in China: An Overview

CAR T-Cell therapy in China is progressing remarkably and has the potential to revolutionize cancer treatment. China is now a pioneer in this industry thanks to its strong regulatory framework and research infrastructure, which have fueled its development.

CAR T-Cell therapy in China is available for approximately $40,000 - $80,000 USD, considerably lower than in other parts of the world, making it an attractive option for international patients.

Furthermore, China's enormous patient population offers a special benefit for carrying out clinical trials and compiling data. With more than 700 ongoing clinical trials, China has emerged as a global leader in CAR T-Cell therapy research and application.

700+
Ongoing Clinical Trials
$40K-80K
Treatment Cost
80%+
Success Rate for Blood Cancers
2017
Year of First Approval

Why Choose CAR T-Cell Therapy in China?

Clinical Trials & Advanced Research

With more than 700 ongoing clinical trials on CAR T-Cell therapy for cancer, China has achieved great strides. Innovative CAR T-cell therapies have been actively developed and tested by Chinese researchers and medical institutes, with a focus on both solid tumors and hematological malignancies.

Cost Effectiveness

CAR T-Cell therapy cost in China is significantly lower than that in countries like the US, UK, Australia, Japan, Korea, and Singapore. While CAR T-Cell therapy in the US can cost $400,000 or more, in China it may cost just $60,000-$80,000 for similar treatments.

Expertise and Experience

Due to its participation in multiple clinical trials and therapies, China has developed a significant amount of knowledge and experience in providing CAR T cell therapy. Chinese medical experts have improved their knowledge of CAR T cell therapy-related problems and their ability to manage them to improve patient outcomes.

International Collaborations

Chinese companies are collaborating with international pharmaceutical giants to develop and improve CAR T-Cell therapies. Examples include collaborations between WuXi AppTec and Juno Therapeutics, and between Legend Biotech and Janssen Biotech.

CAR T-Cell Therapy Process

CAR T Cell therapy for cancer in China involves modifying a patient's own immune cells to recognize and attack cancer cells. This is achieved through genetic engineering, where the patient's T cells are equipped with a chimeric antigen receptor (CAR) that targets cancer-specific proteins.

1

Cell Collection (Apheresis)

T cells are collected from the patient's blood using a process called apheresis. This typically takes a couple of hours.

2

Genetic Modification

T cells are genetically modified in the lab to express a Chimeric Antigen Receptor (CAR) on their surface.

3

Expansion of Cells

The genetically modified T cells are cultivated and multiplied to create a large population of CAR T cells.

4

Conditioning (Lymphodepletion)

Patients undergo conditioning treatment before CAR T-cell infusion to create a favorable environment for the therapy.

5

Infusion of CAR T-Cells

Once prepared, the CAR T cells are injected back into the patient's bloodstream through a drip.

6

Monitoring and Follow-up

Patients are closely monitored for response and potential side effects after the infusion.

Treatment Timeline

The complete CAR T-Cell therapy process typically takes 10-12 weeks:

  • Examination & tests: 1 week
  • Pre-treatment & T-Cell Collection: 1 week
  • T-Cell preparation & return: 2-3 weeks
  • 1st Effectiveness analysis: 3 weeks
  • 2nd Effectiveness analysis: 3 weeks

Cost and Availability

CAR T-Cell therapy in China is significantly more affordable than in Western countries, while maintaining high standards of care and advanced technology.

The cost of CAR T-Cell therapy in China typically ranges from $45,000 to $80,000, compared to $373,000-$475,000 in the United States for similar treatments.

Cost Comparison

Treatment Cost in China Cost in US Approval Status in China
Relma-cel (Carteyva) $60,000 - $80,000 N/A Approved (2021)
Axi-cel (Yescarta equivalent) $70,000 - $90,000 $373,000 Approved (2021)
FUCASO (BCMA CAR-T for myeloma) $200,000 $419,500 (for Abecma) Approved

Factors Affecting Cost

  • Type of CAR-T therapy
  • Complexity of the treatment
  • Hospital expenses
  • Additional care and diagnostics
  • Duration of hospital stay

Top Doctors for CAR-T Therapy in China

Prof. Peihua (Peggy) Lu, MD

Medical Executive President, Lu Daopei Hospital, Beijing

Experience: 27 Years

Dr. Peggy is a clinical professor and medical executive president of Lu Daopei Hospital in China. She has received many awards, including the National Cancer Institute individual fellowship award, and the physician-scientist award from the National Cancer Institute.

Dr. Zhao Defeng, MD

Director, Hematology Department, Beijing Gobroad Hospital

Experience: 24 Years

Dr. Zhao Defeng is the Director of the Hematology Department at Gaobo Medical Beijing Research Center. He has experience with over 1000 patients administering CAR T-cell therapy and has more than 23 ongoing clinical trials on it. He is regarded as one of the best doctors for CAR T-cell therapy in China.

Top Hospitals for CAR T Treatment in China

Peking University Cancer Hospital

Beijing, China

This hospital has become a global leader in the development of CAR T-cell treatment. With a multidisciplinary team consisting of oncologists, immunologists, and geneticists, they have advanced personalized cancer treatment significantly.

Beijing Gobroad Boren Hospital

Beijing, China

Specializes in individualized treatment plans and integrated diagnosis for hematologic diseases. Treatment options include chemotherapy, immunotherapy, targeted therapy, and CAR T-Cell therapy.

Lu Daopei Hospital

Beijing, China

Has significantly advanced the field of CAR T-cell treatment. To date, they claim to have performed more than 1000 CAR T-Cell therapy infusions with encouraging improvements in patient outcomes and survival rates.

The First Affiliated Hospital, Zhejiang University

Hangzhou, China

Founded in 1947, it is the earliest affiliated hospital of Zhejiang University and a leading institution for constructing national-level comprehensive regional medical centers.

Contact Us for CAR T-Cell Therapy in China

If you're considering CAR T-Cell therapy in China, we can help connect you with the best hospitals and doctors based on your specific medical condition and requirements.

Send Your Medical Reports for Evaluation

Please send the following reports for evaluation:

  • Medical summary
  • Latest blood reports
  • Biopsy reports
  • Latest PET Scan
  • Bone marrow biopsy (if available)

Send to: info@cancerfax.com or WhatsApp: +1-213-789-56-55

Our Process

  1. Send Your Reports: Share your medical reports with us
  2. Evaluation & Opinion: We analyze your reports and connect with appropriate hospitals
  3. Medical Visa and Travel: We assist with visa documentation and travel arrangements
  4. Treatment and Follow-up: We provide support throughout your treatment journey